Emmaus Life Sciences, Inc. (EMMA)

Emmaus Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.07	2.13	1.39	2.55	2.02	2.28
Cash & Short-Term Investments	1.07	2.13	1.39	2.55	2.02	2.28
Cash Growth	-19.58%	53.13%	-45.47%	26.03%	-11.32%	-8.36%
Receivables	2.05	2.8	2.62	5.52	0.38	1.04
Inventory	1.91	1.56	1.64	1.71	2.38	4.39
Prepaid Expenses	0.66	0.9	0.89	1.13	1.07	0.99
Other Current Assets	0.31	0.36	0.23	0.6	0.45	0.39
Total Current Assets	6	7.75	6.77	11.51	6.29	9.09
Property, Plant & Equipment	0.83	0.88	1.58	2.4	2.87	3.63
Long-Term Investments	11.66	12.6	15.04	20.98	38.8	43.72
Other Long-Term Assets	0.2	0.21	0.22	0.3	0.26	0.3
Total Assets	18.7	21.44	23.6	35.18	48.23	56.73

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.22	0.28	0.59	0.52	0.3	0.26
Accrued Expenses	27.47	25.52	21.33	18.59	14.45	8.93
Short-Term Debt	10.65	11.15	10.47	11.34	9.18	3.6
Current Portion of Long-Term Debt	17.36	17.38	17.01	16.38	14.66	10.16
Current Portion of Leases	0.35	0.35	2.42	1.64	0.7	0.74
Current Unearned Revenue	13	13	10	10	10	-
Other Current Liabilities	1.49	1.39	1.73	3.04	5.04	13.41
Total Current Liabilities	70.54	69.07	63.56	61.51	54.32	37.1
Long-Term Debt	2.28	2.27	2.25	2.23	3.73	4.65
Long-Term Leases	1.32	1.41	0.82	1.84	2.55	3.26
Long-Term Unearned Revenue	-	-	-	-	-	10
Other Long-Term Liabilities	12.42	12.29	13.47	17.36	21.71	23.17
Total Liabilities	86.56	85.04	80.08	82.94	82.32	78.18

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.07	0.07	0.06	0.06	0.05	0.05
Additional Paid-In Capital	225.99	225.99	225.9	225.33	220.82	220.02
Retained Earnings	-273.4	-270.07	-262.58	-256.12	-252.34	-241.27
Comprehensive Income & Other	-20.52	-19.6	-19.86	-17.03	-2.62	-0.26
Shareholders' Equity	-67.86	-63.61	-56.48	-47.76	-34.09	-21.45
Total Liabilities & Equity	18.7	21.44	23.6	35.18	48.23	56.73

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	31.96	32.56	32.96	33.42	30.82	22.41
Net Cash (Debt)	-30.89	-30.43	-31.57	-30.88	-28.8	-20.13
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.47	-0.48	-0.50	-0.58	-0.58	-0.41
Filing Date Shares Outstanding	70.19	70.19	63.87	61.85	50.93	49.31
Total Common Shares Outstanding	70.19	70.19	63.87	61.85	49.58	49.31
Working Capital	-64.54	-61.33	-56.79	-50	-48.03	-28.01
Book Value Per Share	-0.97	-0.91	-0.88	-0.77	-0.69	-0.43
Tangible Book Value	-67.86	-63.61	-56.48	-47.76	-34.09	-21.45
Tangible Book Value Per Share	-0.97	-0.91	-0.88	-0.77	-0.69	-0.43
Machinery	0.45	0.45	0.39	0.48	0.47	0.45
Construction In Progress	-	-	-	-	-	0.06
Leasehold Improvements	0.02	0.02	0.02	0.04	0.04	0.04

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 10, 2026

Data Sources Report a data error